Reversal of cerebrovascular endothelial dysfunction in diabetes: the effect of allopurinol upon cerebrovascular nitric oxide bioavailability
Completed
- Conditions
- DiabetesNutritional, Metabolic, Endocrine
- Registration Number
- ISRCTN68849312
- Lead Sponsor
- Greater Glasgow NHS Board/Glasgow University (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
1. Type II diabetes less than 5 years duration, treated with diet, metformin thiazolidinediones or a combination
2. Aged greater than 40 years
3. Normal full Bruce protocol exercise treadmill testing (ETT)
4. Favourable temporal bony window
5. HbA1c less than 9%
6. Cholesterol less than 7.5 mmol/l
Exclusion Criteria
1. Greater than 70% Internal carotid artery stenosis
2. Known coronary artery disease
3. Other significant comorbidity
4. Contraindication to allopurinol
5. Concurrent therapy with azathioprine or 6-mercaptopurine
6. Insulin or sulphonylurea treatment
7. Serum creatinine greater than 250 µmol/l
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in internal carotid artery flow following L-NMMA infusion.
- Secondary Outcome Measures
Name Time Method 1. Change in serum urate level<br>2. Change in middle cerebral artery flow velocity